PepGen Inc. (PEPG) stock
PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.36−0.68 (-13.49%)
Close on Nov 13, 2026Market cap $301.97MP/E –Yield –
PepGen r&d expenses
Research and development expenses are spending on new products and technology.
PepGen's R&D Expenses for the twelve months ending Sep 30, 2026 was $53.85M, down 29.3% year over year. For fiscal 2025 it was $71.04M, down 7.1% from the year before. The highest annual figure on record is $76.48M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.04M | -7.1% |
| FY2024 | Dec 31, 2024 | $76.48M | +12.3% |
| FY2023 | Dec 31, 2023 | $68.13M | +26.0% |
| FY2022 | Dec 31, 2022 | $54.08M | +184.6% |
| FY2021 | Dec 31, 2021 | $19.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.48M | +7.8% |
| Q2 FY2026 | Jun 30, 2026 | $12.52M | -31.9% |
| Q1 FY2026 | Mar 31, 2026 | $13.00M | -48.8% |
| Q4 FY2025 | Dec 31, 2025 | $13.85M | -27.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.42M | -24.3% |
| Q2 FY2025 | Jun 30, 2025 | $18.39M | -26.6% |
| Q1 FY2025 | Mar 31, 2025 | $25.38M | +72.3% |
| Q4 FY2024 | Dec 31, 2024 | $18.96M | +16.3% |
| Q3 FY2024 | Sep 30, 2024 | $17.72M | -13.7% |
| Q2 FY2024 | Jun 30, 2024 | $25.06M | +48.1% |
| Q1 FY2024 | Mar 31, 2024 | $14.73M | +2.6% |
| Q4 FY2023 | Dec 31, 2023 | $16.30M | +23.8% |
| Q3 FY2023 | Sep 30, 2023 | $20.54M | +28.7% |
| Q2 FY2023 | Jun 30, 2023 | $16.93M | +18.9% |
| Q1 FY2023 | Mar 31, 2023 | $14.36M | +34.1% |
| Q4 FY2022 | Dec 31, 2022 | $13.17M | +189.9% |
| Q3 FY2022 | Sep 30, 2022 | $15.96M | +179.5% |
| Q2 FY2022 | Jun 30, 2022 | $14.24M | +342.8% |
| Q1 FY2022 | Mar 31, 2022 | $10.71M | +93.6% |
| Q4 FY2021 | Dec 31, 2021 | $4.54M | – |
| Q3 FY2021 | Sep 30, 2021 | $5.71M | – |
| Q2 FY2021 | Jun 30, 2021 | $3.22M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.53M | – |
See a number that looks wrong?